-
Article
Bone metastases in hepatocellular carcinoma: an emerging issue
The nature and the characteristics of bone metastases (BMs) in hepatocellular carcinoma (HCC) have not been fully explored in literature, presumably because HCC skeletal involvement was rarely diagnosed until ...
-
Article
Open AccessEverolimus restrains the paracrine pro-osteoclast activity of breast cancer cells
Breast cancer (BC) cells secrete soluble factors that accelerate osteoclast (OC) differentiation, leading to the formation of osteolytic bone metastases. In the BOLERO-2 trial, BC patients with bone involvemen...
-
Article
Open AccessThe correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
LDH may represent an indirect marker of neo-angiogenesis and worse prognosis in many tumour types. We assessed the correlation between LDH and clinical outcome for biliary tract cancer (BTC) patients treated w...
-
Article
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?
The encouraging results in immunotherapy for melanoma also led the way for translational and clinical research about immune-related mechanisms possibly relevant for gastrointestinal tumours. It is in fact now ...
-
Article
Open AccessMetronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety and efficacy of metronomic capecitabine as second-line ...
-
Article
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
Sorafenib is recommended for the treatment of advanced-stage hepatocellular carcinoma (HCC). Nonetheless, it is expensive, effective in few patients, and may cause significant adverse effects. Therefore, accur...
-
Article
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma
Mast cells are recognized as critical components of the tumor stromal microenvironment in several solid and hematological malignancies, promoting angiogenesis and tumor growth. A correlation between mast cell...
-
Article
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
An Online First version of this article was made available online at https://springer.longhoe.net/article/10.1007/s11523-020-00757-3 on 12 October 2020. Errors were s...
-
Article
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
Inflammation is a long-established hallmark of liver fibrosis and carcinogenesis. Eosinophils are emerging as crucial components of the inflammatory process influencing cancer development. The role of blood eo...
-
Chapter
Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and currently it still remains third leading cause of cancer death.
-
Article
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?
SBA classification is still based on the location of the primary tumor, without genetic information. in the current study, an extensive genetic profile of SBA, was performed in order to identify and quantify t...
-
Article
Open AccessSecond-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
A plethora of second-line therapies have been recently introduced for hepatocellular carcinoma (HCC) treatment with promising results. A meta-analysis of second-line treatments for HCC has been performed to be...
-
Article
Open AccessHSV1 microRNAs in glioblastoma development: an in silico study
Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor. Recent findings highlighted the significance of viral microRNAs (miRs) in regulating post-transcriptional mRNA expression in various hu...
-
Article
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
The TOPAZ-1 phase III trial reported a survival benefit with the anti-programmed cell death ligand 1 (anti-PD-L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary trac...